LifeMD (LFMD) 16th Annual LD Micro Invitational Conference summary

Company overview and strategic direction

• Focused on transforming healthcare delivery at scale as a leading virtual primary care provider, with over 400 million interactions and 322,000 active patients across multiple platforms.

• Expanding beyond men's health into primary care, urgent care, specialty care, psychiatry, cardiology, and a growing women's health segment.

• Leveraging proprietary AI tools to enhance provider efficiency and patient care, with a singular, internally developed platform integrating revenue cycle and supply chain management.

• Integrated 50-state compounding pharmacy enables control over quality and supply chain, positioning for new drug categories like peptides pending regulatory approval.

• Board and management team have deep expertise in AI, healthcare, and technology, with ongoing investments in technology leadership.

Market positioning and growth opportunities

• GLP-1 metabolic health for weight management represents about two-thirds of current business, with 80,000 patients on therapy and strong partnerships with major pharma companies.

• Women's health is a key emerging vertical, targeting a large, underserved market, especially in hormonal management and primary care access.

• Men's health remains profitable but is now a smaller share; innovation and cash flow opportunities continue.

• Psychiatry and cardiology are early-stage but seen as significant future growth drivers, leveraging the virtual care platform and pharmacy integration.

• Anticipates peptides and GLP-1s to comprise up to 75% of revenue in the near term, with women's health and ancillary services growing over time.

Financial performance and outlook

• Achieved consistent revenue growth since going public, with a five-year CAGR of 45%.

• Mid-teens revenue growth expected for the current year, with guidance of $220–$230 million in revenue and $12–$17 million in EBITDA.

• Year-end run rate targets are $250 million in revenue and $25 million in EBITDA, with profitability improving due to alignment with pharma partners and high-growth segments.

• High gross margins in pharmacy operations (~90%) and careful cohort management to optimize LTV/CAC and retention.

• Debt-free with significant cash on hand, enabling growth without immediate need for new capital.